The Hormone Foundation

Patient Alerts

Periodically, The Endocrine Society issues alerts to its physician members to keep them informed of developments or controversies in the field of endocrinology.  Based on these statements, The Hormone Foundation issues similar alerts on topics that affect patients.  Read our recent patient alerts.

• Bone Density Testing: How Often Should Older Women Get the Test? (February 2012)
  
  
• November 17 Deadline to Access Rosiglitazone-containing Medicines for Type 2 Diabetes (November 2011)
  
  
• FDA Announces New Safety Information on Actos (June 2011)
  
  
• Radiation Risk from Japan: Should You Be Concerned? (March 2011)
  
  
• FDA Completes Preliminary Safety Review of Lantus (January 2011)
  
  
• Thyrogen Shortage May Continue Beyond November (November 2010)
  
  
• Thyrogen Shortage Expected Through Mid-November (November 2010)
  
  
• Safety Precautions Following Radioactive Iodine Therapy (October 2010)
  
  
• FDA Announces Change to Bisphosphonate Label (October 2010)
  
  
• Calcium and Heart Attack: Is There a Link? (October 2010)
  
  
• New Information About the Safety of Bisphosphonates (September 2010)
  
  
• FDA Advisory Panel Recommends that Avandia Stay on the Market (July 2010)
  
  
• FDA Issues New Warning on Orlistat (June 2010)
  
  
• FDA Issues New Warning on Propylthiouracil (April 2010)
  
  
• Safety Precautions Following Radioactive Iodine Treatment for Thyroid Cancer  (March 31, 2010)
  
  
• High Blood Pressure Treatment in People with Diabetes (March 2010)
  
  
• Long-Term Use of Bisphosphonates: Is It Safe? (March 2010)
  
  
• Renewed Concerns about Rosiglitazone (Avandia) and Heart Disease Risk (February 2010)
  
  
• New Study on A1c Levels: Making Sense of It All (January 2010)